These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 32876000)

  • 41. Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management.
    Nandipati KC; Raina R; Agarwal A; Zippe CD
    Drugs Aging; 2006; 23(2):101-17. PubMed ID: 16536634
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
    Yafi FA; Sharlip ID; Becher EF
    Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior.
    Hedelin H; Ströberg P
    Drugs; 2005; 65(16):2245-51. PubMed ID: 16266193
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy.
    Kimura M; Caso JR; Bañez LL; Koontz BF; Gerber L; Senocak C; Donatucci CF; Vujaskovic Z; Moul JW; Polascik TJ
    BJU Int; 2012 Dec; 110(11 Pt C):E931-8. PubMed ID: 22520165
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel Emerging Therapies for Erectile Dysfunction.
    Kim S; Cho MC; Cho SY; Chung H; Rajasekaran MR
    World J Mens Health; 2021 Jan; 39(1):48-64. PubMed ID: 32202086
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy.
    Sexton WJ; Benedict JF; Jarow JP
    J Urol; 1998 Mar; 159(3):811-5. PubMed ID: 9474156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Therapy of erectile dysfunction--public health aspects].
    Junuzović D; Mehmedbasić S; Aganović D; Smajlović F
    Med Arh; 2004; 58(1 Suppl 1):66-8. PubMed ID: 15077460
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review.
    Isidori AM; Buvat J; Corona G; Goldstein I; Jannini EA; Lenzi A; Porst H; Salonia A; Traish AM; Maggi M
    Eur Urol; 2014 Jan; 65(1):99-112. PubMed ID: 24050791
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of erectile dysfunction in patients with Peyronie's disease using sildenafil citrate.
    Levine LA; Latchamsetty KC
    Int J Impot Res; 2002 Dec; 14(6):478-82. PubMed ID: 12494281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low-intensity shock wave therapy ameliorates erectile dysfunction in men with pelvic fractures associated with urethral injury.
    Wang CJ; Lu YM; Li CC; Wu WJ; Chien TM
    Int J Impot Res; 2019 May; 31(3):218-222. PubMed ID: 30420772
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An overview of the diagnosis and treatment of erectile dysfunction.
    Sivalingam S; Hashim H; Schwaibold H
    Drugs; 2006; 66(18):2339-55. PubMed ID: 17181376
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An update on the drug safety of treating erectile dysfunction.
    Gul M; Serefoglu EC
    Expert Opin Drug Saf; 2019 Oct; 18(10):965-975. PubMed ID: 31433252
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.
    Megas G; Papadopoulos G; Stathouros G; Moschonas D; Gkialas I; Ntoumas K
    BJU Int; 2013 Jul; 112(2):E169-76. PubMed ID: 23253640
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Available and future treatments for erectile dysfunction.
    Dinsmore WW
    Clin Cornerstone; 2005; 7(1):37-45. PubMed ID: 16156422
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlates of PDE5i use among subjects with erectile dysfunction in two population-based surveys.
    Travison TG; Hall SA; Fisher WA; Araujo AB; Rosen RC; McKinlay JB; Sand MS
    J Sex Med; 2011 Nov; 8(11):3051-7. PubMed ID: 21834873
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Application of the vacuum erectile device in penile rehabilitation for erectile dysfunction after radical prostatectomy].
    Lin H; Wang G; Wang R
    Zhonghua Nan Ke Xue; 2015 Mar; 21(3):195-9. PubMed ID: 25898548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Core document on erectile dysfunction: key aspects in the care of a patient with erectile dysfunction.
    Brotons FB; Campos JC; Gonzalez-Correales R; Martín-Morales A; Moncada I; Pomerol JM
    Int J Impot Res; 2004 Oct; 16 Suppl 2():S26-39. PubMed ID: 15496854
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does testosterone supplementation increase PDE5-inhibitor responses in difficult-to-treat erectile dysfunction patients?
    Aversa A; Francomano D; Lenzi A
    Expert Opin Pharmacother; 2015 Apr; 16(5):625-8. PubMed ID: 25643866
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sexual dysfunction in diabetes.
    Tamás V; Kempler P
    Handb Clin Neurol; 2014; 126():223-32. PubMed ID: 25410225
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PDE5 inhibitors: considerations for preference and long-term adherence.
    Smith WB; McCaslin IR; Gokce A; Mandava SH; Trost L; Hellstrom WJ
    Int J Clin Pract; 2013 Aug; 67(8):768-80. PubMed ID: 23869678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.